IBP-9414
Prevention of Necrotizing Enterocolitis (NEC) and improvement of feeding tolerance in very low birth weight preterm infants
Key Facts
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB is dedicated to developing novel, microbiome-based treatments for life-threatening conditions affecting newborns, particularly premature infants. Its core technology involves the administration of specific, naturally occurring bacterial strains to support gut health and prevent devastating diseases. The company's most advanced program, IBP-9414, has completed a pivotal Phase 3 trial (NCT03453177) and is preparing for regulatory submissions, positioning IBT as a leader in neonatal microbiome therapeutics. Its mission is to address the significant unmet medical need in neonatology with safe and effective biological products.
View full company profile